GSA Capital Partners’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-78,148
| Closed | -$33K | – | 2119 |
|
|
2025
Q4 | $33K | Sell |
78,148
-3,584,330
| -98% | -$1.9M | ﹤0.01% | 1589 |
|
|
2025
Q3 | $2.47M | Buy |
3,662,478
+1,417,029
| +63% | +$764K | 0.21% | 44 |
|
|
2025
Q2 | $1.22M | Buy |
2,245,449
+1,279,247
| +132% | +$760K | 0.09% | 341 |
|
|
2025
Q1 | $634K | Buy |
966,202
+934,649
| +2,962% | +$990K | 0.06% | 633 |
|
|
2024
Q4 | $32K | Sell |
31,553
-314,079
| -91% | -$574K | ﹤0.01% | 1546 |
|
|
2024
Q3 | $299K | Sell |
345,632
-587,544
| -63% | -$430K | 0.02% | 1213 |
|
|
2024
Q2 | $334K | Buy |
933,176
+568,892
| +156% | +$307K | 0.02% | 1210 |
|
|
2024
Q1 | $244K | Sell |
364,284
-711,406
| -66% | -$516K | 0.02% | 1319 |
|
|
2023
Q4 | $584K | Buy |
1,075,690
+515,959
| +92% | +$238K | 0.05% | 692 |
|
|
2023
Q3 | $336K | Sell |
559,731
-247,223
| -31% | -$265K | 0.03% | 1012 |
|
|
2023
Q2 | $1.05M | Buy |
806,954
+587,866
| +268% | +$803K | 0.1% | 284 |
|
|
2023
Q1 | $386K | Buy |
219,088
+18,623
| +9% | +$53.1K | 0.04% | 872 |
|
|
2022
Q4 | $629K | Buy |
200,465
+185,415
| +1,232% | +$720K | 0.08% | 456 |
|
|
2022
Q3 | $74K | Sell |
15,050
-7,735
| -34% | -$39.7K | 0.01% | 1399 |
|
|
2022
Q2 | $94K | Sell |
22,785
-13,193
| -37% | -$57.1K | 0.01% | 1230 |
|
|
2022
Q1 | $209K | Buy |
+35,978
| New | +$214K | 0.03% | 1152 |
|
|
2021
Q4 | – | Sell |
-32,240
| Closed | -$290K | – | 1757 |
|
|
2021
Q3 | $290K | Buy |
+32,240
| New | +$319K | 0.03% | 1043 |
|
|
2020
Q3 | – | Sell |
-10,223
| Closed | -$92K | – | 1371 |
|
|
2020
Q2 | $92K | Buy |
+10,223
| New | +$94.8K | 0.05% | 493 |
|
|
2020
Q1 | – | Sell |
-10,189
| Closed | -$85K | – | 1504 |
|
|
2019
Q4 | $85K | Buy |
+10,189
| New | +$93.7K | 0.01% | 1350 |
|
|
2019
Q2 | – | Sell |
-65,031
| Closed | -$620K | – | 1702 |
|
|
2019
Q1 | $620K | Sell |
65,031
-13,569
| -17% | -$139K | 0.06% | 559 |
|
|
2018
Q4 | $902K | Buy |
+78,600
| New | +$976K | 0.1% | 257 |
|
|
2018
Q2 | – | Sell |
-23,221
| Closed | -$441K | – | 1904 |
|
|
2018
Q1 | $441K | Buy |
+23,221
| New | +$496K | 0.02% | 1132 |
|
|
2015
Q2 | – | Sell |
-63,576
| Closed | -$997K | – | 2163 |
|
|
2015
Q1 | $997K | Buy |
+63,576
| New | +$984K | 0.04% | 861 |
|
|
2014
Q2 | – | Sell |
-15,249
| Closed | -$276K | – | 1948 |
|
|
2014
Q1 | $276K | Buy |
+15,249
| New | +$294K | 0.02% | 1192 |
|
Other funds holding SGMO
AC
VCM
VFT
GSA Capital Partners's SGMO Position: Q1 2026 in Review
GSA Capital Partners sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2026, closing a stake of 78,148 shares — an estimated $33K sold.
GSA Capital Partners first reported a position in SGMO in Q1 2014 and held it in 24 quarters. The position peaked at $2.47M in Q3 2025. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.
- GSA Capital Partners reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2026 after selling out during the quarter.
- GSA Capital Partners sold 78,148 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $33K.
- GSA Capital Partners first reported a position in SANGAMO THERAPEUTICS INC in Q1 2014 and held it in 24 quarters.
- GSA Capital Partners's SANGAMO THERAPEUTICS INC position peaked at $2.47M in Q3 2025.
- 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.
Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.